Industry
Biotechnology
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
March 21, 2024 | 10:53 am
Portfolio Pulse from Benzinga Insights
March 20, 2024 | 8:20 pm
Portfolio Pulse from Benzinga Newsdesk
March 20, 2024 | 8:19 pm
Portfolio Pulse from Benzinga Insights
March 20, 2024 | 9:32 am
Portfolio Pulse from Benzinga Insights
March 19, 2024 | 4:01 pm
Portfolio Pulse from saritha@benzinga.com
November 09, 2023 | 9:56 pm
Portfolio Pulse from Benzinga Insights
November 08, 2023 | 5:00 pm
Portfolio Pulse from Benzinga Newsdesk
November 02, 2023 | 11:46 am
Portfolio Pulse from Benzinga Newsdesk
October 13, 2023 | 12:37 pm
Portfolio Pulse from richadhand@benzinga.com
August 11, 2023 | 9:30 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.